The table below shows HALOZYME THERAPEUTICS, INC.'s income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
Line item
Q1 2026
Q3 2025
Q2 2025
Q1 2025
Q3 2024
Q2 2024
Revenue
$376.71M
$354.26M
$325.72M
$264.86M
$290.08M
$231.35M
Cost of revenue
$79.24M
$55.24M
$46.36M
$48.40M
$49.43M
$39.61M
Gross profit
-
-
-
-
-
-
R&D
$25.56M
$17.25M
$17.54M
$14.80M
$18.46M
$21.04M
HALO annual revenue (10-K history)
HALOZYME THERAPEUTICS, INC. reported annual revenue of $1.40B for fiscal year 2025. That is up 37.6% from $1.02B in fiscal 2024. Over the 10 fiscal years shown, annual revenue grew from $146.69M (FY 2016) to $1.40B. Figures come from the company's audited annual reports as filed with the SEC.
